OVCAR-8-Luc Cells
USD 800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Información general
| Descripción | OVCAR-8-Luc cells are a bioluminescent derivative of the human ovarian adenocarcinoma cell line OVCAR-8, which was originally established from an adult patient with advanced-stage disease. These cells have been genetically engineered to stably express luciferase, an enzyme that catalyzes light emission in the presence of its substrate, enabling highly sensitive, non-invasive monitoring of cellular activity. The parental OVCAR-8 line is characterized by aggressive growth, genomic instability, and features representative of high-grade serous ovarian cancer, making it a widely used model for studying ovarian tumor biology. The incorporation of luciferase allows OVCAR-8-Luc cells to be used in longitudinal in vivo imaging applications, particularly in xenograft and orthotopic tumor models, where tumor burden and metastatic dissemination can be quantitatively tracked over time using bioluminescence imaging. These cells retain key molecular and phenotypic traits of the parental line, including alterations in pathways relevant to ovarian cancer progression such as p53 dysfunction and dysregulated cell cycle control. Consequently, OVCAR-8-Luc cells are well suited for evaluating therapeutic efficacy, tumor growth kinetics, and metastatic behavior, as well as for studying tumor microenvironment interactions in preclinical research. |
|---|---|
| Organismo | Human |
| Tejido | Ovary |
| Enfermedad | Adenocarcinoma |
| Lugar de metástasis | Primary tumor site (ovary) |
| Aplicaciones | Ovarian cancer research; bioluminescence imaging in xenograft/orthotopic models; in vivo tumor burden tracking; drug efficacy and pharmacodynamics; PARP inhibitor and platinum sensitivity studies; peritoneal metastasis modeling; ovarian cancer immunotherapy evaluation |
| Sinónimos | OVCAR 8, NIH:OVCAR-8, OVCAR8, Ovcar8, OVCAR.8, OVCA8, OVCAR-8/EGFP_LC3 |
Características
| Edad | 64 years |
|---|---|
| Género | Female |
| Origen étnico | Caucasian |
| Morfología | Epithelial-like |
| Tipo de célula | Epithelial cells |
| Propiedades de crecimiento | Adherent |
Datos normativos
| Referencia | OVCAR-8-Luc (Cytion catalog number 305697) |
|---|---|
| Nivel de bioseguridad | 1 |
| NCBI_TaxID | 9606 |
| N.º de acceso de Cellosaurus | CVCL_2169 |
| Estado de los OGM | GMO-S1: This human ovarian carcinoma cell line (OVCAR-8-Luc) contains a lentiviral firefly-Luc reporter construct, enabling bioluminescent tracking. The insert is stably integrated. This classification applies only within Germany and may differ elsewhere. |
Datos biomoleculares
| Expresión de proteínas | Luc |
|---|
Manejo
| Medio de cultivo | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Suplementos | Supplement the medium with 10% FBS |
| Reactivo de disociación | Accutase |
| Densidad de siembra | 1-3 x 104 cells/mL |
| Renovación de fluidos | 2 to 3 times per week |
| Medio de congelación | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| Descongelación y cultivo de células |
|
| Atmósfera de incubación | 37°C, 5% CO2, humidified atmosphere. |
| Condiciones de envío | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Condiciones de almacenamiento | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Control de calidad y análisis molecular
Certificado de análisis (CoA)
| Número de lote | Tipo de certificado | Fecha | Número de catálogo |
|---|---|---|---|
| 305697-090326 | Certificado de análisis | 13. Apr. 2026 | 305697 |